Compound Name:  CLS-TA, triamcinolone acetonide injectable suspension 
Protocol Number:  CLS100 1-302 
IND Number:  115683  
Study ID: [REMOVED]  
Protocol Title  AZALEA: Open -label Safety Study of Suprachoroidal 
Triamcinolone Acetonide Injectable Suspension in Patients 
with Non -Infectious Uveitis  
Sponsor:  Clearside Biomedical, Inc.  
900 North Point Parkway, Suite 200  
Alpharetta, GA 30005  
Issue Date:  
Protocol Amendment 1 Date:  16 January 2017  
27 Apr il 2017  
 
CLS 1001-302 Clinical Protocol 
CLS-T A (triamcinolone acetonide) Injectable Suspension Clearside Biomedical, Inc. 
Project: 
Compound Number/Name: 
Protocol Number: 
Phase: 
IND Number: 
Protocol Title: 
Sponsor: 
Medical Monitor: 
Original Protocol Issue Date: 
Amendment #1 Issue Date: CLEARS I DE 
Clinical Protocol CLSlOOl-302 
1001 
CLS-T A, triamcinolone acetonide injectable suspension 
CLS 1001-302 
3 
115683 
AZALEA: Open-label Safety Study of Suprachoroidal 
Triamcinolone Acetonide Injectable Suspension in Patients 
with Non-Infectious Uveitis 
Clearside Biomedical, Inc. 
900 North Point Parkway, Suite 200 
Alpharetta, GA 30005, USA 
Peter Nicholas, MD, PhD 
16JAN2017 
27 APR 2017 
CONFIDENTIAL '11-1/fR. 020r1 
Date 
This protocol contains confidential information about a product provided by Clearside Biomedical, Inc. 
This information is provided for the exclusive use of the Investigators participating in this study. Any 
and all confidential information contained herein may not be disclosed to any other person or party 
without the prior written consent of Clearside Biomedical, Inc. 
27 April 2017 Page 1of58 
CONFIDENTIAL 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 2 of 58 
CONFIDENTIAL  INVESTIGATOR’S AGREEMENT  
 
I have received and read the Investigator’s Brochure for  CLS -TA. I have read the CLS1001-302 
protocol and agree to conduct the study as outlined. I agree to maintain the confidentiality of all 
information received or developed in connection with this protocol.  
 
 
 
  
             
Printed Name of Investigator  
             
Signature of Investigator  
       
Date  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 3 of 58 
CONFIDENTIAL  PROCE DURES IN CASE OF EME RGENCY  
 
Table 1: Emergency Contact Information 
Role in Study  Name  Telephone number  
Medical Monitor  
(24-Hour emergency contact)  Peter Ni
cholas, MD, PhD 919.259.9521 
Sponsor Clinical Lead  Ellie Smith  678.448.4717 
Principal  Investigator  The Coordinating Principal Investigator will be appointed by the 
Sponsor before the end of the study.  As part of his or her 
responsibilities, the Coordinating Principal Investigator will review the final Clinical Study Report and will sign the report to confirm that it accurately describes the conduct and results of the 
study.  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 4 of 58 
CONFIDENTIAL  2. SYNOPSIS  
Name of Sponsor/Company:  
Clearside Biomedical, Inc.  
Name of Investigational Product:  
CLS-TA (triamcinolone acetonide ) injectable suspension 
Name of Active Ingredient:  triamcinolone acetonide  
Title of Study: AZALEA: Open -label Safety Study of Suprachoroidal Triamcinolone Acetonide 
Injectable Suspension in Patients with Non- Infectious Uveitis  
Study center(s): Multi -center  
Protocol Number:  CLS100 1-302  
Studied perio d: 6 Month Duration  
Estimated date first subject  enrolled: 1Q 2017 
Estimated date last subject  compl eted: 2Q2018 Phase of development:  
Phase 3  
Objectives:  
Primary:  To evaluate the s afety of suprachoroidally administered CLS -TA in subjects with non-
infectious uveitis. 
Secondary:  
• To assess changes to signs and complicat ions of uveitis   
• To collect use inform ation on the suprachoroidal injection procedure 
• To determine systemic exposure to triamcinolone acetonide  following suprachoroidal injection  
Number of subjects (planned): Approximately 35 
Diagnosis and main criteria for inclusion:  
Patients diagnosed with non -infectious  uveitis for which the administration of local corticosteroid 
therapy would be a viable treatment option 
Investigational product, dosage and mode of administration:  
CLS-TA, injectable suspension, 4.0 mg in 100 µL administered via suprachoroidal injection  
Criter ia for evaluation:  
The primary endpoint is the i ncidence of t reatment- emergent adverse events and serious adverse 
events, grouped by organ system, relatedness to study medication, and severity  
Statistical methods:  
All data collected in the study database will be presented in the listings. Listings will include change 
from baseli
ne. Baseline is Visit 2 (Day 0).  
The safety population will include all subjects who are administered at least one dose of CLS- TA 
(4 mg/100 µL).  Al
l analyses will be based on safety population.   
Descriptive statistics are displayed to provide an overview of the study results.  Descriptive statistics 
include n, mea
n, median, minimum, and maximum values.  The distribution of responses (n, %) will 
be tabulated for each category of response. 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 5 of 58 
CONFIDENTIAL  3. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES  
TABLE OF CONTENTS  
2. SYNOPSIS  ...................................................................................................................4  
3. TABLE OF CONTENTS, L IST OF TABLES, AND LIST OF FIGURES  .................5  
4. LIST OF ABBREVIATION S.....................................................................................10  
5. INTRODUCTION  ......................................................................................................11  
5.1. Disease Background  ...................................................................................................11  
5.2. Scientific Rationale  .....................................................................................................11  
5.3. Description of Investigational Product .......................................................................12  
5.4. Summary of Clinical Experience and Justification of Dose Selection  .......................12  
6. TRIAL OBJECTIVES AND PURPOSE  ....................................................................14  
6.1. Primary Objective  .......................................................................................................14  
6.2. Secondary Objective  ...................................................................................................14  
7. INVESTIGATIONAL PLAN  .....................................................................................15  
7.1. Overall Study Design  ..................................................................................................15  
7.2. Endpoints ....................................................................................................................15  
7.2.1.  Primary Endpoint ........................................................................................................15  
7.2.2.  Safety Endpoints  .........................................................................................................15  
7.2.3.  Additional Endpoints ..................................................................................................15  
7.3. Number of Subjects ....................................................................................................16  
7.4. Treatment Assignment  ................................................................................................16  
8. SELECTION AND WITHDRAWAL OF SUBJECTS  ..............................................17  
8.1. Inclusion Criteria  ........................................................................................................17  
8.2. Exclusion Criteria  .......................................................................................................17  
8.2.1.  Ophthalmic Exclusion Criteria  ...................................................................................17  
8.2.2.  General Exclusion Criteria  .........................................................................................18  
8.3. Subject Withdrawal Criteria  .......................................................................................18  
8.4. Visit Procedure Descriptions ......................................................................................19  
8.4.1.  General Procedures  .....................................................................................................19  
8.4.2.  Re-screening Procedures  ............................................................................................19  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 6 of 58 
CONFIDENTIAL  8.4.3.  Visit 1 – Screening (Day -30 to 0) ..............................................................................19  
8.4.4.  Visit 2 –Treatment (Day 0)  .........................................................................................20  
8.4.5.  Follow- Up: Visit 3 – Week 4 (Day 28 ±5) .................................................................21  
8.4.6.  Follow- Up: Visit 4 – Week 8 (Day 56 ±5) .................................................................22  
8.4.7.  Visit 5 – Week 12 – Treatment #2 (Day 84 ±5) .........................................................22  
8.4.8.  Follow- Up: Visit 6 – Week 16 (Day 112 ± 5) & Visit 7 – Week 20 (Day 140 
±5) ...............................................................................................................................23  
8.4.9.  Visit 8 – Week 24 End of Study (Day 168 ± 5) or Early Termination .......................24  
8.4.10.  Unscheduled Visit .......................................................................................................24  
9. TREATMENT OF SUBJECTS ..................................................................................25  
9.1. Treatments to be Administered  ...................................................................................25  
9.2. Study Eye Determination  ............................................................................................25  
9.3. Treatment of the Fellow Eye  ......................................................................................25  
9.4. Additional Treatment  ..................................................................................................25  
9.4.1.  Rescue Criteria  ............................................................................................................25  
9.5. Concomitant Medications ...........................................................................................26  
9.6. Treatment Compliance  ................................................................................................26  
9.7. Randomization and Masking ......................................................................................26  
10. STUDY DRUG MATERIALS  AND MANAGEMENT  ...........................................27  
10.1.  Study Drug  ..................................................................................................................27  
10.2.  Study Drug Packaging and Labeling  ..........................................................................27  
10.3.  Study Drug Storage  .....................................................................................................27  
10.4.  Study Drug Preparation  ..............................................................................................27  
10.5.  Administration  ............................................................................................................27  
10.6.  Study Drug Accountability .........................................................................................27  
10.7.  Study Drug Handling and Disposal ............................................................................28  
11. ASSESSMENTS OF EFFIC ACY  ..............................................................................29  
11.1.  Best Corrected Visual Acuity  .....................................................................................29  
11.2.  Central Subfield Thickness as Measured by Spectral Domain Optical 
Coherence Tomography ..............................................................................................29  
11.3.  Pharmacokinetics Assessments  ..................................................................................29  
12. ASSESSMENTS OF SAFET Y ..................................................................................30  
12.1.  Safety Parameters  .......................................................................................................30  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 7 of 58 
CONFIDENTIAL  12.1.1.  Intraocular Pressure ....................................................................................................30  
12.1.2.  Slit-Lamp Biomicroscopy ...........................................................................................30  
12.1.3.  Cataract Lens Grading  ................................................................................................30  
12.1.4.  Anterior Chamber Cells  ..............................................................................................30  
12.1.5.  Anterior Chamber Flare  ..............................................................................................31  
12.1.6.  Indirect Ophthalmoscopy ............................................................................................31  
12.1.7.  Fluorescein Angiography ............................................................................................32  
12.1.8.  Fundus Photography ...................................................................................................32  
12.1.9.  Resting Heart Rate and Blood Pressure ......................................................................32  
12.1.10.  Pregnancy Test  ............................................................................................................32  
12.1.11.  Central Laboratory Tests  ............................................................................................32  
12.1.12.  Review of Body Systems  ............................................................................................33  
12.2.  Adverse and Serious Adverse Events .........................................................................33  
12.2.1.  Definition of Adverse Events .....................................................................................33  
12.2.2.  Relationship to Study Drug ........................................................................................33  
12.2.3.  Recording Adverse Event ...........................................................................................34  
12.2.4.  Intensity ......................................................................................................................34  
12.2.5.  Reporting Adverse Events ..........................................................................................35  
12.2.6.  Follow-up of AEs and SAEs .......................................................................................35  
13. STATISTICAL CONSIDERATIONS  .......................................................................37  
13.1.  Determination of Sample Size and Level of Significance  ..........................................37  
13.2.  Subject Disposition, Demographic and Baseline Characteristics ...............................37  
13.3.  Analysis Populations ..................................................................................................37  
13.3.1.  Safety Population ........................................................................................................37  
13.3.2.  Pharmacokinetic Population .......................................................................................37  
13.4.  Analysis Methods .......................................................................................................37  
13.4.1.  Primary Safety Analysis  .............................................................................................37  
13.4.2.  Secondary Safety Analysis  .........................................................................................38  
13.4.3.  Pharmacokinetic Analysis  ..........................................................................................39  
13.4.4.  Procedure for Accounting for Missing, Unused or Spurious Data .............................39  
14. DIRECT ACCESS TO SOU RCE DOCUMENTS  .....................................................40  
14.1.  Study Monitoring ........................................................................................................40  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 8 of 58 
CONFIDENTIAL  14.2.  Audits and Inspections ................................................................................................40  
14.3.  Institutional Review Boards/Independent Ethics Committees  ...................................41  
15. QUALITY CONTROL AND QUALITY ASSURANCE  .........................................42  
16. ETHICS  ......................................................................................................................43  
16.1.  Ethical Review  ............................................................................................................43  
16.2.  Ethical Conduct of the Study ......................................................................................43  
16.3.  Written Informed Consent ..........................................................................................43  
17. DATA HANDLING AND RECORDKEEPING  .......................................................44  
17.1.  Inspection of Records .................................................................................................44  
17.2.  Retention of Records ..................................................................................................44  
18. PUBLICATION POLICY  ..........................................................................................45  
19. REFERENCES  ...........................................................................................................46  
20. APPENDICES  ............................................................................................................47  
APPENDIX A.  TIME AND EVENTS SCHE DULE ..................................................................48  
APPENDIX B:   SUMMARY OF CHANGES  ............................................................................50  
 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 9 of 58 
CONFIDENTIAL  LIST OF TABLES  
Table 1:  Emergency Contact Information ...................................................................................3  
Table 2:  Abbreviations and Specialist Terms ...........................................................................10  
Table 3:  Anterior Chamber Cell Grading Scale  ........................................................................31  
Table 4:  Anterior Chamber Flare Grading Scale  ......................................................................31  
Table 5:  Scale for Determining Degree of Vitreous Haze  ........................................................32  
 
LIST OF FIGURES  
Figure  1: Anatomy of the Eye ....................................................................................................12  
Figure  2: Study Schedule ...........................................................................................................16  
 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 10 of 58 
CONFIDENTIAL  4. LIST OF ABBREVIATION S  
The following abbreviations and specialist terms are used in this study protocol. 
Table 2: Abbreviati ons and Specialist Terms  
Abbreviation or Specialist Term  Explanation  
AE Adverse event 
BCVA  Best corrected visual acuity  
CRC  Central reading center  
CRF  Case report form  
CST Central subfield thickness 
ETDRS  Early Treatment of Diabetic Retinopathy Study  
FA Fluorescein angiography/angiogram  
IEC Independent E thics C ommittee  
IND Investigational New Drug  
IOP Intraocular pressure 
IRB Institutional R eview Board 
IVT Intravitreal  
ME Macular edema  
MedDRA  Medical Dictionary for Regulatory Activities  
OCT  Optical c oherence tomography 
PK Pharmacokinetics  
RVO Retinal vein occlusion 
SAE  Serious adverse event 
SC Suprachoroidal 
SCS Suprachoroidal space 
SD-OCT  Spectral -domain optical coherence tom ography  
TA Triamcinolone acetonide 
TEAEs  Treatment -emergent adv erse events  
US United States  
VEGF  Vascular endothelial growth factor  
VA Visual acuity  
 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 11 of 58 
CONFIDENTIAL  5. INTRODUCTION 
Clearside Biomedical is developing a proprietary formulation of triamcinolone acetonide (CLS 
TA) to treat non- infectious uveitis . This multicenter, open- label  study is designed to evaluate th e 
safety of  suprachoroidal ly injected  CLS -TA in subjects with non- infectious uveitis . 
Suprachoroidal (SC) injection is a novel drug delivery approach that employs Clearside’s proprietary suprachoroidal space (SCS™) microinjector and allows drugs to be precisely administered to the SCS via a minimally invasive injection procedure. This injection has been 
shown in animal models to allow distribution of drug candidates dominantly to the posterior 
segment ocular tissues while limiting exposure to anterior structures in the eye, thereby providing the potential for improved efficacy and safety. The purpose of this study is to expand the safety database of suprachoroidally injected CLS -TA in patients with non -infectious uveitis . 
5.1. Disease Background  
Uveitis is the fifth most common cause of visual loss in the developed world (Gol dstein , 2009; 
Wood, 2011; Miserocchi, 2013). Significant vision loss can occur in up to 35% of children and adults, and uveitis accounts for 5% - 20% of legal blindness in both the United States (US) and 
Europe, and perhaps as much as 25% of blindness in the developing world (Rothova, 1996; 
Bodaghi, 2001). 
There are a number of causes associated with this vision loss including cataract formation or 
progression, chor
ioretinal scarring, retinal detachment, and secondary glaucoma, but the 
dominant cause of vis ion loss within uveitis comes from chronic macular edema ( ME), 
accounting for about one-third of visual impairment or blindness (Wood, 2011; Dick, 1994; Karim, 2013). Approximately 30% of all uveitis patients and up to 60% of intermediate- and 
pan-uveitis patients experience ME  (Lardenoye, 2006). 
5.2. Scientific Rationale  
Clearside is developing CLS -TA, a proprietary TA formulation, for the treatment of non-
infectious uveit is administered by SC injection. This therapy for uveitis is part of Clearside’s 
paradigm of developing drug treatments for unmet or underserved blinding eye diseases where the pathologies dominantly originate or manifest in the choroid and the retina.  
Uveitis is commonly treated with corticosteroids and other immunomodulatory agents; such 
treatments
 are either systemic or local. The challenge with systemic, frequently  oral, 
cortico steroid treatments for ophthalmic inflammatory conditions is that these tre atments are 
often associated with adverse events (AEs) such as peptic ulcerations, osteoporosis, necrosis of 
the hip, weight gain, muscle weakness, hyperglycemia, and systemic hypertension. All currently used modes of steroid administration for ophthalmic conditions, including local administrations , 
are associated with increases in intraocular pressure (IOP) that could result in glaucoma, progression of glaucoma, and to both the formation and the progression of cataracts (Karim, 2013).  
The potential advantages of using suprachoroidal administration  to precisely  
 provide local 
corticosteroid therapy to the affected tissues of the eye are that it can result in robust efficacy 
based upon data from animal models and from Phase 1/2 and Phase 2 clinical data . Furt her, the 
unique distribution of drug following suprachoroidal administration confining it to the posterior 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 12 of 58 
CONFIDENTIAL  segment and sparing anterior segment portions of the eye, along with the extremely low systemic 
steroid exposure to other organs in the body, can provide differentiating efficacy along with the potential for improved safety.   
5.3. Description of Investigational Product  
CLS-TA, triamcinolone acetonide injectable suspension, is a preservative- free, terminally 
sterilized, aqueous suspension, formulated for administration into the eye. It will be administered as a single SC injection of 4 mg in 100 µL. The suprachoroidal spa ce (SCS) is the region of the 
eye between the sclera and the choroid (Figure 1).  
Figure  1: Anatomy of the Eye 
  
 
Additional  i
nformation regarding CLS -TA, tria m cinolone acetonide injectable suspension, is 
available in the Clinical Investigator’s Brochure.  
5.4. Summary of Clinical Experience and Justification of Dose Selection  
Triamcinolone acetonide (TA) has been used safely and effectively in human ocular therapeutics 
to treat conditions involving inflammation for over 50 years. The initial recommended dose of 
the TA formulation approved by the US Food and Drug Administration for ocular indications is 
4 mg in 100 μL (TRIESENCE Prescribing Information, 2007). The dose of CLS- TA 
administered as a single suprachoroidal injection will be similar (4 mg in 100 μL). TRIESENCE 
and CLS- TA contain the same active and inactive ingredients at approximately the same 
concentrations. Both formulations are aqueous suspensions that have been terminally sterilized 
and designed for opht halmic use.  
Clearside has completed 2 clinical trials in patients with non -infecti ous  uveitis and one clinical 
trial in patients with retinal vein occlusion ( RVO). 
The completed clinical study, CLS1001-101 ([STUDY_ID_REMOVED]), was a Phase 1/2, open- label, 
safet y a
nd tolerability study in subjects with intermediate, posterior, or pan non- infectious uveitis  
(Goldstein 2016). Each subject received a single SC injection of 4 mg in 100 µL TA (TRIESENCE®). Nine of the 11 subjects in the safety analysis set (82%) compl eted the 26 -week 
study. All subjects had at least one AE, with a total of 37 AEs reported. One serious adverse 

CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 13 of 58 
CONFIDENTIAL  event (unrelated pulmonary emboli; SAE) occurred. No deaths were reported. No significant 
increases in IOP were reported. The most commonly reported AE, eye pain, was reported in 5 subjects.  All subjects in the per -protocol (n=8) analysis set showed improvements in BCVA in 
this study.  
The completed clinical study, CLS1001-201 ([STUDY_ID_REMOVED]), was a Phase 2, randomized, masked safety
 and efficacy stud y in subjects with ME associated with non-infectious uveitis. 
Twenty -two subjects were assigned to receive a single SC injection of CLS -TA, either 4 mg in 
100 µL or 0.8 mg in 100 µL in a 4:1 randomization. Subjects in the 4.0 mg treatment group were observed to have a mean reduction in central subfield thickness (CST) of 164 microns (p=0.002) 
when measured from Baseline at 2 months. One SAE (unrelated atrial fibrillation) occurred. No 
subjects discontinued due to an AE, and there were no Investigator- report ed increases in IOP at 
follow-up visits. 
The completed clinical study, CLS1003-201 (CT02303184), was a Phase 2, randomized, masked 
safety a nd 
efficacy study in subjects with ME following RVO. Forty- six subjects were randomly 
assigned 1:1 to either SC injection of CLS-TA administered in conjunction with an intravitreal 
(IVT) injection of aflibercept (ACTIVE), or an IVT injection of aflibercept alone (CONTROL). 
Subjects were observed to have a mean reduction in CST of 445 µm in the ACTIVE group and 
342 µm in the CONTROL group when measured from Baseline at 3 months. Mean 
improvements in best corrected visual acuity ( BCVA ) were 16, 20 and 19 letters in the ACTIVE 
group and 11, 12 and 11 letters in the CONTROL group at Months 1, 2 and 3 respectively. Sixty 
percent fewer additional intravitreal aflibercept injections (p=0.013) were required in the 
ACTIVE group receiving the combination of suprachoroidal CLS- TA and intravitreal aflibercept 
compared to subjects in the CONTROL arm. No subjects discontinued due to an AE and no 
SAEs were reported. Two subjects in the active group reported 2 events each of ocular 
hypertension and IOP increase.  All events were mild or moderate in intensity and considered to be related to study drug. 
Safety profiles have been similar in all three studies with eye pain being the most commonly 
reported AE . 
Additional information regarding clinical experience with TA administered to the 
SCS is available in the Investigator’s Brochure.  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 14 of 58 
CONFIDENTIAL  6. TRIAL OBJECTIVES AND  PURPOSE  
The purpose of this open- label stu dy is to evaluate  the safety of suprachoroidally administered  
CLS-TA for the treatment of non-infectious uveitis.  
6.1. Primary O bjective 
The primary objective of this study is to evaluate the safety of suprachoroidally administered 
CLS-TA in subjects with  non- infectious uveitis.   
6.2. Secondary Objective 
The secondary objectives of the study are:  
• To assess changes to signs and complications of uveitis 
• To collect
 use information on the suprachoroidal injection procedure 
• To determin
e systemic exposure to triamcin olone acet oni de after suprachoroidal injection  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 15 of 58 
CONFIDENTIAL  7. INVESTIGATIONAL PLAN  
7.1. Overall Study Design  
This is a Phase 3, open- label, multi- center study to assess the safety of 4 mg of CLS -TA 
administered via suprachoroidal injection for the treatment of subjects with non-infectious 
uveitis.   
The study design includes 8 clinic visits over a maximum of 29 weeks.  Subject eligibility will be 
establishe
d at Visit 1 during the screening process (Day -30 to 0).  Eligible subjects will return to 
the clinic for Visit 2 (Day 0).  Visit 1 and Visit 2 can occur on the same day. Qualified subjects 
will receive two unilateral suprachoroidal injections of CLS-TA administered to the study eye, approximately 12 weeks apart (Visit 2 and Visit 5).  Follow up visits will be conducted every 4 
weeks up to 24 weeks (Visit 8).  Subjects will have a final evaluation conducted 24 w eeks (Visit 
8) following Treatment #1 (Day 0).  All subjects will be included in pharmacokinetic evaluations at Visits 2, 3, 5 and 8. 
Subjects will be assessed via study procedures outlined in the time and events schedule.   
7.2. Endpoints  
7.2.1. Primary Endpoint  
The primary endpoi nt is the i ncid ence of treatment -emergent adverse events (TEAEs) and SAEs, 
grouped by organ system, relatedness to study medication, and severity.  
7.2.2. Safety  Endpoi nts 
• Percentage of subjects whose IOP increases are >5 and > 10 mmHg from their own 
baseline meas
urement at each follow -up visit (except Visits 2 & 5 [post-dose])  
• Percentage of subjects whose IOP increases to a reading > 30 mmHg at each follow -
up visit (ex
cept Visits 2 & 5 [post-dose]) 
• Percentage of subjects who require 1 or more addit ional IOP  lowering medications at 
any follow -up visit (except Visits 2 & 5 [post-dose]) 
• Percentage of subjects who experience an 11 – 20 mm,  21-30 mm, >30 mm r ise in 
IOP 30 min post injection 
• Mean change in lens grading based on standardized cataract gradi ng system 
a
ssessment  
7.2.3. Additional  End points  
• User evaluation and information pertaining to the use of the microinjector during the 
injection pr
ocedure  
• Triamcinolone acetonide blood concentrations prior to each dose (Visits 2 and 5), 4 
weeks foll
owing the first dose (Visit 3) and at 24 weeks (Visit 8)  
• Percentage change in anterior chamber cells  and flare,  a nd vitreous haze 
• Mean change from baseline in  Early T reatment of Diabetic Retinopathy Study  
(ETDRS ) BCVA  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 16 of 58 
CONFIDENTIAL  • Mean change from baseline in  CST   
• Percentage of subjects with <300 micron CST 
• Percentag
e of subjects with a decrease in systemic concomitant uveitis medications  
• Percent
age of subjects in whom any additional therapy was initiated to manage 
uveitis  
7.3. Number of Subjects 
Approximately 35 subjects with non- infectious uveitis will be enrolled into the study.  
7.4. Treatment Assignment  
After Screening (Day -30 to Day 0) and Baseline assessments on Day 0, subjects will be 
assigned to the study treatment that consists of two unilateral suprachoroidal injections o f 4 mg 
(100 µL of 40 mg/mL) CLS -TA administered to the study eye, approximately 12 weeks apart 
(Visit 2 and Visit 5).   
  
Figure  2: Study Schedule   
 
C
LS-TA= Triamcinolone Acetonide Injectable Suspension 

CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 17 of 58 
CONFIDENTIAL  8. SELECTION AND  WITHDRAWAL OF SUBJE CTS  
8.1. Inclusion Criteria 
Individuals are eligible for participation in this study if s/he meets all of the following criteria:  
1. A diagnosis of non- infectious  uveitis of any etiology for which the administration of local 
corticosteroid ther apy would be a viable treatment option; either anterior -, intermediate -, 
posterior- or pan -uveitis  are acceptable; both active and inactive uveitis are acceptable  
2. ETDRS  BCVA sc ore of ≥ 5 letters read in the study eye  
3. Understands the language of the informed consent; willing and able to provide written 
informed cons
ent prior to any study procedures; willing to comply with the instructions 
and attend all scheduled study visits 
4. At least 18 years of age  
8.2. Exclusion Criteria  
8.2.1. Ophthalmic Exclusion Criteria  
An individual is ineligible for participation in this study if s/he meets any of the following criteria:  
1. Ha
s significant media opacity in the study eye precluding evaluation of the retina and 
vitreous  
2. A
ny active ocular disease or infection in the study eye other than uveitis  
3. Intraocul
ar pressure > 22 mmHg or uncontrolled glaucoma (open angle or angle closure) 
in the study
 eye at Visit 1; subjects are not excluded if IOP is ≤ 22 mmHg in the study 
eye with no more than 2 IOP lowering medications  
4. Has a h istory of severe glaucoma as defined by optic nerve damage (cup/disc ratio of       
≥ 0.9 or any not
ching of optic nerve to the rim)   
5. History of any vitreoretinal surgery (examples include but are not limited to scleral 
buckle, retr
ieval of a dropped nucleus or intraocular lens)  in the study eye; prior 
photocoagulation and IVT injections are acceptable; prior cataract extraction, Yttrium-
Aluminum-Garnet laser capsulotomy, and pars plana vitrectomy is allowed, but must have been performed at least 3 months prior to Visit 2  
6. Has had cyclodestructive procedures ,filtration surgeries , or laser t
 rabeculoplasty  in the 
study eye in the 3 months prior to Visit 2 
7. Has high myopia in the study eye defined as a spherical equivalent > -6 diopters or an 
axial le
ngth ≥ 26 mm  
8. Has h ad photocoagulation or cryotherapy in the study eye within the 6 months prior to 
Visit 2  
9. H
as had any IVT injection of anti -vascular  endothelial growth factor treatment 
(bevacizumab, aflibercept, pegaptanib or ranibizumab) in the study eye in the 30 days prior to Visit 2  
10. In the study eye, any topical ocular corticosteroid in the 10 days prior to Visit 2; intraocula
r and periocular corticosteroid injection in the 2 months prior to Visit 2; an 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 18 of 58 
CONFIDENTIAL  Ozurdex® implant in the 6 months prior to Visit 2; Retisert®or Iluvien® implant in the 3 
years prior to Visit 2 
8.2.2. General Excl usion Criteria   
Individuals are not eligible for participation in this study if s/he meets any of the following 
criteria:  
11. Fe
male subjects who are pregnant, lactating or planning a pregnancy.  Femal es of 
childbe
aring potential must agree to submit to a pregnancy test at screening and agree to 
use an acceptable method of contraception throughout participation in the study.  Acceptable methods of contraception include double barrier methods (condom with spermicide or diaphragm with spermicide), hormonal methods (oral contraceptives, implantable, transdermal, or injectable contraceptives), or an intrauterine contraceptive device with a documented failure rate of less than 1% per year.  Abstinence may be considered an acceptable method of contraception at the discretion of the Investigator, but the subject must agree to use one of the acceptable birth control methods if she becomes sexually active.  
12. Any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participatio
n in the study (eg . unstable medical status including uncontrolled elevated 
blood pressure, cardiovascular disease, and glycemic control) or put the subject at risk due to study treatment or procedures 
13. Likely need for hospitalization or surgery within the study period, including planned electi ve
 surgery or hospitalization that cannot be deferred 
14. Hypersensitivity to any component of the CLS-TA, fluorescein, or to topical anesthetics 
15. Is curr
ently enrolled in an investigational drug or device study or has used an 
investiga
tional drug or device within 30 days of Visit 2 OR was ever enrolled in a 
previous clinical study of CLS- TA 
16. Has used acetazolamide (Diamox®) 1 week prior to Visit 2  
17. Has taken systemic corticosteroids at doses greater than 20 mg per day for oral prednisone (or
 equivalent for other corticosteroids) in the 2 weeks prior to Visit 2; 
subjects on 20 mg or less per day can be enrolled; decreases and termination of dose are 
allowable during the study  
18. Is currently using prescribed nonsteroidal anti- inflammator y drugs (excluding 
over-the-counter use) unless the dose has been stable for at least 2 weeks prior to Visit 2; decreases and termination of dose are allowable during the study  
19. Is currently  using pres
 cribed immunomodulatory therapies, unless the dose has been 
stable for at least 2 weeks prior to Visit 2; decreases and termination of dose are allowable during the study 
8.3. Subject Wit
 hdrawal Criteria  
Subjects may withdraw from the study at any time and for any reason without obligation.  
Subjects ma
y be removed from the study at the Investigator’s discretion.   
Subjects who withdraw prematurely from the study will be asked to complete study assessments at the E arly 
Termination V isit. If an SAE is unresolved at the time of the subject’s final study 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 19 of 58 
CONFIDENTIAL  visit, the Investigator should make every attempt to follow up until the SAE is resolved or 
stabilized, the subject is lost to follow -up, or there is some other resolution of the event.  
8.4. Visit Procedure D escriptions  
8.4.1. General Procedures  
The study will consist of up to 8 s tudy visits over a maximum of 29 weeks .  Subjects are 
expected to  attend all study visits.   All ocular assessments at Visit 1 and Visit 8 will be 
performed on both eyes.  IOP will be collected in both eyes at all visits. All other ocular 
assessments at all other visits (Visits 2 -7) will be collected  on the study eye only.   
Subjects will be screened for entry at Visit 1  (Days - 30 to 0) and the study eye will be identified .  
Each eligible subject will return to the clinic within 30 days to be treated at Visit 2  (Day 0 ). Visit 
1 and Visit 2 can occur on the same day. After baseline assessments on Day 0 , subjects will 
receive an active SC dose of CLS-TA in the study eye. Subjec ts will be assessed after injection 
for safety . 
Additional safety follow-up visits will occur every 4 weeks  for 24 weeks.  Subjects will receive a 
second SC injection of CLS- TA at Visit 5 (Week 12 ).  The final study visi t will occur at Visit 8 
(Week 2 4).  
8.4.2. Re-screening Pro cedures   
Subjects may be re- screened if  the reason for their initial screening failure has changed. A 
subject who is designated as a screen failure before being randomly assigned at Visit 2 (Day 0) 
may be re -screened up to 2 additional times, for a total of 3 screenings, upon Sponsor approval.  
Subjects who are re- screened are req uired to sign a new consent form. Screening assessments 
must be repeated if timings for the assessments fall outside of the specified study windows.  
8.4.3. Visit 1 – Screeni ng (Day -30 to 0) 
At Visit 1, subjects will be screened for eligibility.  B efore any stu dy-specific assessments are 
performed, written informed consent will be obtained for each subject.  During Visit 1, the 
following procedures will be performed  by study staff : 
1. Obtain written informed consent 
2. Assign s
ubject number 
3. Collect de
mographics, medical  and ocular  history    
4. Review current and prior concomitant medications  
5. Measure
 resting heart rate and blood pressure  
6. Collect
 blood and urine for central lab tests prior to fluorescein angiography ( FA) 
7. Collect s
erum or urine for local p regnancy  test on females of childbearing potential  
8. Perform ophthalmic assessments on both eyes:  
a. ETDRS BCVA  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 20 of 58 
CONFIDENTIAL  b. Slit-lamp biomicroscopy, including dilated lens grading  
c. IOP (Goldmann applanation tonometry) 
d. Dilated ind
irect ophthalmoscopy 
e. Fundus photography and upload images  to t he Central Reading Center  (CRC)  
f. SD-OCT  and upload image s to the CRC 
g. FA and upload images  to the CRC  
9. Pe
rform a review of systems  
10. Verify s
ubject eligibil ity based on Inclusion/Exclusion requirements 
11. Determine study eye  based upon  eye specific eligibility  criteria  (see Section 9.2) 
12. Schedule subject to return for Visit 2, Treatment , or continue on t o Visit 2 procedures   
8.4.4. Visit 2 –Treat ment (Day 0) 
Visit 2 may occur on the same day as Visit 1 (Screening) but must occur within 30 days of Visit 
1 (Screenin
g). The following procedures will be performed by study staff : 
8.4.4.1. Pre-Injectio n Procedures  
The following must be performed prior to the i njection  of C LS-TA (the same day as the 
injection) . If Visit 1 and Visit 2 are performed on the same day, the pre-injection procedures in 
Visit 2 can be wai ved: 
1. Assess for AEs  
2. Review chan
ges to concomitant medications  
3. Review lab
 results for any clinically significa nt abnorma lities  that would exclude the 
subject from entry 
4. Measure resting heart rate and blood pressure  
5. Perform
 ophthalmic assessments on the study eye only, unless otherwise designated:  
a. ETDRS BCVA  
b. Slit-lamp bi
omicroscopy, including dilated lens grading 
c. IOP (Gol
dmann applanation tonometry), both eyes 
d. Dilated  ophthal
moscop y 
e. SD-OCT and upload images  to the CRC 
6. C
ollect a blood sample for PK analysis ; blood must be c ollected PRIOR to dosing 
8.4.4.2. Injection Pro cedure and Immediate Post- Injection  Assessments  
For details on the injection procedure, please see the Investiga tor Site File .  
1. Confirm study eye 
2. Retrieve
 study drug kit number  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 21 of 58 
CONFIDENTIAL  3. Prepare eye for injection  per the investigator’s standard practice    
4. The injecting investigator should administer suprachoroidal injection of CLS- TA 
procedure t
o the study eye; s ee Manual of Procedures  for detailed instructions  
5. Immediately following the  injection,  assess study eye by  indirect ophthalmoscopy 
8.4.4.3. Post-Inject i on Procedures  
The following assessments must occu r following t he injection  of CLS -TA: 
1. Assess for AEs  
2. Review chan
ges to concomitant medications  
3. Perform
 ophthalmic assessments on the study eye only:  
a. Perform slit -lamp biomi croscopy  
b. Perform indirect ophthalmoscopy 
c. Evaluate IOP  approxi mately 30 minutes post- injection : 
• If IOP remains elevated, subject must remain on site until IOP is under 
control per i
nvestigator judgment 
• If IOP is  < 30  mmHg , the  subject may leave the clinic  
4. Document injection procedure use information 
5. Schedul e subje
ct to r eturn for next visit  
8.4.5. Follow- Up: V isit 3  – Week 4 (Day 28 ±5) 
Visit 3  should be 42 ±5  days fro m Visit 2.  The following procedures wi ll be performed by study 
staff at Visit 3 : 
1. Assess for AEs  
2. Review chan
ges to concomitant medications   
3. Perform
 ophthalmic assessments on the study eye only, unless otherwise designated:  
a. ETDRS BCVA  
b. Slit-lamp bi
omicroscopy, including dilated lens grading  
c. IOP (Gol
dmann applanation tonometry), both eyes 
d. Dilated  indir
ect ophthalmoscopy 
e. SD-OCT and uploa
d images  to the CRC 
4. C
ollect a blood sample fo r PK analy sis 
5. Schedule s ubject to re turn for next visit 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 22 of 58 
CONFIDENTIAL  8.4.6. Follow- Up: Visit 4 – Week 8 (Day 56 ±5) 
Visit 4 should be 56 ±5  days from V isit 2. The following procedures will be performed by study 
staff at Visit 4: 
1. Assess for AEs  
2. Review chan
ges to concomitant medications  
3. Perform o
phthalmic assessments on the study eye only, unless otherwise designated:  
a. ETDRS BCVA  
b. Slit-lam
p biomicroscopy, including dilated lens grading  
c. IOP (Goldmann applanation tonometry), both eyes 
d. Dilate
d indirect ophthalmoscopy 
e. SD-OCT and upload images  to the CRC 
4.
 Schedule subject to return for next visit 
8.4.7. Visit 5 – Wee
k 12 – T re atment  #2 (Day 84 ±5) 
At Visit 5, subjects will receive their second, unilateral, suprachoroidal injection of CLS- TA. 
The followin
g Visit 5 procedures will be performed by study staff:  
8.4.7.1. Pre-Injectio n Procedures  
The following must be performed prior to the i njection  of C LS-TA (the same day as the 
injection) : 
1. Assess for AEs  
2. Review chan
ges to concomitant medications  
3. Measure r
esting heart rate and blood pressure  
4. Confirm stud
y eye  
5. Perform
 ophthalmic assessments on the study eye only, unless otherwise designated:  
a. ETDRS BCVA  
b. Slit-lamp bi
omicroscopy, including dilated lens grading  
c. IOP (Gol
dmann applanation tonometry), both eyes 
d. Dilated i
ndirect ophthalmoscopy 
e. SD-OCT and upload images  to the CRC 
7. C
ollect a blood sample for PK analysis ; blood must be c ollected PRIOR to dosing 
8.4.7.2. Injection Procedure and Immediate Post -Injectio n Assessments  
For details on the injection procedure, please see the Investiga tor Site File .  The Vi sit 5 injection 
procedure should be identical to the Visit 2 injection procedure. 
1. Confirm study eye 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 23 of 58 
CONFIDENTIAL  2. Retrieve study drug kit number  
3. Prepare eye for injection per the investigator’s standard practice  
4. The injec
ting investigator should administer a suprachor oidal inje ction of CLS- TA in the 
study eye  
5. Immediately following the  injection,  assess study eye by  indirect ophthalmoscopy 
8.4.7.3. Post-Injecti on Procedures  
The following assessments must occur following the injectio n: 
1. Assess for A
Es 
2. Review chan
ges to concomitant  medication s 
3. Perform ophthalmic assessments on the study eye only :  
a. Perform slit -lamp biomi croscopy  
b. Perform indirect  ophthalmoscop y 
c. Evaluate IOP approximately  30 minutes post -injection : 
• If IOP remains elevated, subject must remain on site until IOP is under 
control per i
nvestigator judgment 
• If IOP is < 30 mmHg, the subject may leave the clinic  
4. Document i
njection procedure use information 
5. Schedule s
ubject to return for next visit 
8.4.8. Follow- Up
: V isit 6 – Week 16 (Day 112 ± 5) & Visit 7 – Week 20 (Day 140 ±5) 
Visit 6 should be 112 ± 5 days from Visit 2 . Visit 7 should be  140 ±5  from Visit 2 .  The 
following procedures will be performed by study staff: 
1. Assess for AEs  
2. Review chan
ges to concomitant medications   
3. Perfor
m ophthalmic assessments on study eye only, unl ess other wise designated :  
a. ETDRS BCVA  
b. Slit-lam
p biomicroscopy, including dilated lens grading  
c. IOP (Goldmann applanation tonometry), both eyes 
d. Dilate
d indirect ophthalmoscopy 
e. SD-OCT and upload images  to the CRC 
4. S
chedule subject to return for next visit 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 24 of 58 
CONFIDENTIAL  8.4.9. Visit 8 – Week 24  End of Study (Day 1 68 ± 5) or Early Termination  
Visit 8 should be 168 ± 5 days from Visit 2  or at the time o f early termination .  The following 
Visit 8 procedures will be performed by study staff:  
1. Assess for AEs  
2. Review chan
ges to concomi tant medicatio ns  
3. Measure resting heart rate and blood pressure  
4. Collec t
 blood and urine for central lab tests prior to FA  (including serum  pregnancy test 
on females of childbearing potential) 
5. Collect a blood sample for PK analysis  
6. Perform a r
eview of systems  
7. Perform
 ophthalmic assessments on both eyes , unless o therwise designated :  
a. ETDRS BCVA  
b. Slit-lamp bi
omicroscopy, including dilated lens grading  
c. IOP (Gol
dmann applanation tonometry), both eyes 
d. Dilate
d indirect ophthalmoscopy 
e. Fundus photography and upload images to the CRC 
f. SD-OCT and upload images  to the CRC 
g. FA
 and upload images to the CRC  
8.4.10. Unschedule
d Vi sit 
To ensure subject safety during the study, any subject who requires additional follow-up or 
treatment for
 any reason at any time during the study that does not fall on a scheduled study visit 
should have that visit recorded as an Unscheduled Visit.  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 25 of 58 
CONFIDENTIAL  9. TREATMENT OF SUBJECTS 
9.1. Treatments to be Administered  
Treatment will consist of two  unilateral suprachoroidal injections of 4 mg of CLS -TA in 100 µL, 
administered 12 weeks apart .  
Approximately 35 subjects will be enrolled.  The CLS -TA injection s w ill occur at Visit 2 
(Day  0) and at Visit 5 (Day 84 ± 5).   
All SC  injections may only be performed by trained Investigators. Training will be documented 
by the Spo
nsor in writing. Training documentation will be maintained at the site as well as with 
the Sponsor.  
 Detailed instructions on the SC injection procedure can be found in the Investigativ
 e Site File . 
 
9.2. Study Eye Determination  
The study eye will be the eye receiving the SC CLS -TA injection .  The determination of the 
study eye will be based on S creening /Baseline  information and will be determined prior to 
injection . 
If both eyes meet study criteria, then the right eye should be designated as the study eye.  The 
eye that is no
t designated as the study eye will be denoted as the fellow eye.  
9.3. Treatment  of the Fellow Eye  
Subjects may have bilateral disease, but only one eye will be designated the study eye and 
treated .  
Local medications are permitted for the fellow eye during the course of this trial. The choice of local o cular t 
herapy for the fellow eye is not subject to the requirements of this protocol. 
Systemic therapy for diseases of the fellow eye is subject to the list of prohibited medications below.  Medications used for therapy of the fellow eye will be recorded in the subject’s medical chart and the case report form (CRF).   
9.4. Additional Treatment  
If at any time  during the study a subject is considered at immediate risk for a vision -threatening 
event, the Investigator should immediately follow best medical practice in the Investigator’s judgment for treating the subject.  All additional therapy will be recorded in the subject’s medical chart and the CRF.  
9.4.1. Rescue Criteria  
B
eginning at Week 4 (Visit 3), if any of the following criteria are met in the study eye, the use of 
a treatment ma
y be introduced.  The therapy implemented is left to the discretion of the 
Investi gator.   
• A decrease of 10 or more ETDRS BCVA letters read from baseline (Day 0)  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 26 of 58 
CONFIDENTIAL  • An increase in CST of ≥ 100 µm or 20%, whichever is lower, from baseline (Day 0) 
based on the CST measurement at the clinical site  
• A ≥ 1.5- step incre ase from baseline (Day 0) i n the level of inflammation (eg, anterior 
chamber cells  or flare,  or vitreous haze) or an increase from 3+ to 4+  
• A decrease of 10 or more ETDRS BCVA letters read from the best ETDRS BCVA data observed durin
g the study, along with an increase in other signs or complications 
associated with the patient’ s uveitis  
• In the investigator’s medical judgement, the uveitic complications in the study eye have not improved and t
he condition needs to be addressed 
9.5. Concomitant Medications  
The list of prohibited medications provided below is not intended to be comprehensive, but rather to help guide the Investigator’s medical ju dgment.  In cases where a subject  presents with 
a medication not included on the following list, or should there be any question on the part of the 
Investigator, Investigators are encouraged to confer with the Medical Monitor for any 
clarification.  
Use of the following medications are prohibited at any time during the study: 
• Any corticosteroid implant (ie , Ozurdex
®, Iluvien® or Retisert™) in the s tudy eye  
• Topical, periocular or IVT corticos teroids in the study eye  
• Anti-angiogenic drugs (anti- VEGF) in t h e study eye or systemically ( including 
pegaptanib sodium, bevacizumab, ranibizumab) 
• Any i nvestigat ional drug or device 
In cases where there is anticipated need for the above listed medications during the study or if a 
subject  pre
sents to the Investigator having initiated treatment during the study with one of these 
medications or classes of medications, it is the responsibility of the Investigator to notify the 
Sponsor immediately.  If additional therapy is necessary  to treat uveitis in the study eye  and 
normal standard of care requires these medications, they will be recorded in the subject’s case report form  and should follow the guidelines presented for R escue C riteria .  Subjects will not be 
discontinued from the study due to initiation/change in a prohibited medication. 
9.6. Treatment Compliance  
Study drug will only be administered by trained study investigators (P rincipal Investigator or 
Sub-Investigator) in the office at Visit 2  and Visit 5.  No study drug will be dispensed to 
subjects ; subject treatment compliance is not applicable.   
9.7. Randomization and Masking  
This study is neither randomized nor is the study treatment mask ed. Investigators, study staff, 
subjects and the sponsor will be aware of the investigational treatment provided to the subject. 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 27 of 58 
CONFIDENTIAL  10. STUDY DRUG MATERIALS AND MANAGEMENT  
10.1. Study Drug  
CLS-TA, triamcinolone acetonide injectable suspension, is a s terile, preservative- free, aqueous 
suspension formulated for administration into the eye. The drug product is terminally sterilized 
and is intended for single use. CLS-TA is supplied as a 40 mg/mL sterile suspension in a            2 mL/13  mm TopLyo
® single -use vial with a rubber stopper and an aluminum seal. 
Additional information regarding CLS- TA is availab le in the Investigator’s Brochure.  
10.2. Study Drug Packaging and Labeling  
The study drug kits for SC injection of CLS-TA will be supplied to each site by the Sponsor (or designee) and will be labeled for “Investigational Use only”. 
10.3. Study Drug Storage  
CLS-TA will be stored at ambient temperatures between  15°C and  25°C (59 °F-77° F) in an  area 
with limited, controlled acc ess and temperature monitoring; do not freeze. CLS-TA should be 
protected from light by storing in the carton provided. 
10.4. Study Drug Preparation  
Shake the vial of CLS -TA vigorously for 10 seconds to ensure a uniform suspension before 
withdrawing the product from the vial.  
10.5. Administration  
CLS-TA will be administered as a single SC injection of 4 mg in 100 µL. 
All CLS -TA injections may only be performed by trained Investigators. Training will be 
documented by
 the Sponsor in writing. Training documentation will be maintained at the site as 
well as with the Sponsor.  
Detailed instructions on the CLS-TA injection procedure can be found in the Investigative Site 
File. 
The date
 and time of the injection will be recorded in the subject’s medical char t and the CRF. 
A
ll needles used, the needle length used for injection and procedure use information will also be 
recorded.  
10.6. Study Drug Accountability  
Accountability of study drug kits will be conducted by either designated study staff and/or the study monitor. Accountability will be ascertained by performing reconciliation between the number of study drug cartons (kits and components) sent to the site and the number used and unused at the time of reconciliation.   
Study drug shipment records will be verified and accountability performed by comparing the 
shipment invent
ory sheet to the actual quantity of drug and injectors received at the site. 
Accurate records of receipt and disposition of the study drug and injectors (eg, dates, quantit y, 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 28 of 58 
CONFIDENTIAL  subject number, kits used, and  kits unused) must be maintained by the Investigator  or his/her 
designee.  
10.7. Study Drug Handling and Disposal  
At the end of the study and after study drug kit accountability has been verified, all study drug 
(used and unused vials) and unused microinjector components will be returned to the Sponsor (or 
designee) or destroyed at the site and documented according to  the site’s standard process. Any 
used injectors and vials of study drug involved in a product complaint must be maintained and 
return to the Sponsor (or designee). All study drug and injector accounting procedures must be 
completed before the study is considered complete.  
 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 29 of 58 
CONFIDENTIAL  11. ASSESSMENTS OF EFFICACY  
For additional information on an assessment, see the Investigative Site File.  
11.1. Best Corrected Visual Acuity  
BCVA  will be evaluated by ETDRS using electronic visual acuity or standardized lighting and 
lanes. The method of visual acuity assessment should remain consistent throughout a subject’s 
study participation. The results will be reported as the number of letters read following refraction . Visual acuity testing should precede any examination requiring contact with the eye.  
In order to provide standardization and well-controlled assessments of BCVA during the study, all BCVA ass
essments must be performed by trained staff who are certified on the study 
procedure using certified VA equipment/lanes. 
11.2. Central Subfield Thickness as Measured by Spectral Domain Optical 
Coherence Tomography  
Retinal thickness and disease characterization will be assessed via spectral domain – optical 
coherence tomography ( SD-OCT ). The SD-OCT instrument and technician must be certified 
before screening any subjects. The technician is encouraged to use the same certified equipment 
throughout the subject’s study participation. All images  should be taken by the same technician , 
whenever possible, on each  subject per research site. De -identified images will be uploaded to 
the CRC.  
11.3. Pharmacokinetics Assessments  
Blood samples for measurement of CLS- TA plasma concen trations will be collected by 
venipuncture by qualified study personnel. A single blood sample will be obtained from each 
subject at the following time points: Day 0 (Visit 2) pre -dose, Week 4 (Visit 3)  any time during 
visit, Week 12 (Visit 5)  pre-dose and Week 24 (Visit 8)  any time during visit. Blood samples 
will be processed and shipped to a central lab as outlined in the manual of procedures for the study.  
 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 30 of 58 
CONFIDENTIAL  12. ASSESSMENTS OF SAFET Y 
For additional information on an assessment, see the Investigative Site File.  
12.1. Safety Parameters  
12.1.1. Intraocular Pressure  
Intraocular pressure will be measured by applanation tonometery and results will be recorded in 
mmHg.  Goldmann appl
anation tonometry should be used at all visits. Tonopens may be used for 
post-injection pressure checks. A single measurement will be made at approximately the same time of day.  The technician is encouraged to use the same tonometry method throughout the subject’s study participation.  Tonometers must be calibrated for accuracy before the first subject screening at that site and according to the manufacturer specifications during the study, until the last subject  has exited the study at that site.  
12.1.2. Slit-Lamp Biomi c
 roscopy  
Slit-lamp biomicroscopy, including magnification, will be performed consistent with standard clinical practic
e.  This procedure should be conducted in the same manner for all subjects and 
will in clude an assessment of each of the following as normal or abnormal: eyelids, cornea, 
anterior chamber, iris and  lens.  All abnormal findings will be described .  
12.1.3. Cataract Lens G rading 
If an abnormal finding of cataract is noted during the slit- lamp exam, th e cataract s hould be 
graded  for nuclea r opalescence, cortical opacity and posterior subcapsular opacity.  Graders 
must verify training on the grading procedures. 
12.1.4. Anterior Chamb er Cells  
Anterior chamber cells will be assessed clinically using a field size o f 1 mm slit beam and u sing 
a standardized grading scale ranging from 0 to 4 +, as defined in Table 3 (SUN, 2005).  
 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 31 of 58 
CONFIDENTIAL  Table 3: Anterior Chamber Cell Grading Scale 
Score  Cells in Field  
0 <1 
0.5+ 1-5 
1+ 6-15 
2+ 16-25 
3+ 26-50 
4+ >50 
12.1.5. Anterior Chamber Flare  
Anterior chamber flare will be assessed clinically via slit lamp  using a standard ized scale ranging 
from 0 to 4, as defined in  Table 4 (SUN, 2005).  
Table 4: Anterior Chamber Flare Grading Scale 
Score  Description  
0 None 
1+ Faint  
2+ Moderate (iris and lens details clear)  
3+ Marked (iris and lens details hazy)  
4+ Intense (fibrin or plastic aqueous) 
 
12.1.6. Indirect  Ophthalmoscopy   
Indirect ophthalmoscopy should be performed according to the Investigator’s standard 
procedure. This procedur
e should be the same for all subjects observed at the Investigator’s site. 
The fundus will be examined thoroughly and the following variables will be assessed as normal or abnormal (including but not limited to): vitreous, retina, choroid, and optic nerve/disc, appearance of vessels, absence of neovascularization.   
12.1.6.1. Vitreous Haze  
Vitr
eous haze will be assessed clinically via indirect ophthalmoscopy using a standardized 
photographic scale r
anging from 0 to 4, as defined in Table 5 (Nussenblatt 1985 as modified in 
Lowder 2011).  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 32 of 58 
CONFIDENTIAL  Table 5: Scale for Determining Degree of Vitreous Haze 
Score  Description  
0 no inflammation  
+0.5 trace inflammation (slight blurring of the optic disc margins and/or loss 
of the nerv
e fiber layer reflex)  
+1 mild blurring of the retinal vessels and optic nerve 
+1.5 optic nerve head and posterior retina view obscuration greater than +1 but less than +2  
+2 moderate blurring of the optic nerve head 
+3 marked blurring of the optic nerve head 
+4 optic nerve head not visible 
 
12.1.7. Fluorescein A ngiography  
Fluorescein angiography will be performed for anatomic assessments and will include the area of 
fluorescein
 leakage, area of capillary nonperfusion, the presence of retinal vascular and optic 
nerve head staining, and retinal pigment epithelium abnormalities. Digital equipment will be 
registered and photographers certified for the imaging procedures. De- identified images will be 
uploaded to the CRC.  
12.1.8. Fundus Photogr aphy  
Color fundus photographs will be obtained. It is recommended that when both fundus 
photographs and FA
 are conducted in the same visit, the fundus photographs should be taken 
first. All photographs should be taken by the same photographer, whenever possible, on all 
subjects per research site. Digital equipment will be reg istered and photographers certified for 
the imaging procedures. De-identified images will be uploaded to the CRC. 
12.1.9. Resting Hea rt Rate and Blood Pressure  
Resting heart rate and resting blood pressure (systolic and diastolic, preferably on the same group each  time) 
 will be measured at Visits 1, 2, 5 and 8 after the subject has rested for about 5 
minutes.  
12.1.10. Pregnancy T est 
Pregnancy tests will be performed on all females of childbearing potential. Urine or serum pregnancy te
sts may be performed locally . 
12.1.11. Central La bor atory Tests 
Non-fasting clinical laboratory tests will be performed at Visits 1 and 8. These laboratory tests 
include ser
um chemistry, hematology, and urinalysis and are to evaluate any underlying disease 
condition. 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 33 of 58 
CONFIDENTIAL  12.1.12. Review of Body Systems  
A review of body systems will include an assessment of each of the following as normal or 
abnormal: ski
n, cardiovascular, respiratory, neurological and musculoskeletal systems .  All 
abnormal findings will be described .  This exam  may be performed by any medical doctor  or 
legally qualified personnel per local laws/regulations.  
12.2. Adverse and Serious Adverse Events  
12.2.1. Definition of Adverse Events  
12.2.1.1. Adverse Event   
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medic
al condition  after or during exposure to a pharmaceutical product, whether or not 
considered causally related to the product. In clinical studies, an AE can include an undesirable medical condition occurring at any time, including baseline or washout periods, even if no study treatment has been administered.  
All AEs that occur after any subject has signed consent, before treatment, during treatment, or during the stud
y participation, whether or not they are related to the study, must be recorded on 
the forms provided. 
12.2.1.2. Serious Adv erse Event  
An SAE is an AE occurring during any study phase (ie, baseline, treatment, washout, or follow-
up), and at any dos
e of the investigational product, comparator, or placebo, that fulfils one or 
more of the following: 
• Results in death  
• Is immediately life -threate ning 
• Requires in -patient hos pitalization or prolongation of existing hospitalization  
• Results in persistent or significant disability or incapacity  
• Results
 in a congenital abnormality or birth defect 
• Is an important medic al event th at may jeopardize the subject or may require medical 
intervention to prevent one of the outcomes listed above. 
All SAEs that occur after any subject has been enrolled, before treatment, during treatment, or 
during study pa
rticipation, whether or not they are related to the study, must be recorded. 
12.2.2. Relations hip to Study Drug  
An Investigator who is qualified in medicine must make the determination of relationship to the investigat
ional product for each AE (Unrelated or Related). The Investigator should decide 
whether, in his or her medical judgment, there is a reasonable possibility that the event may have 
been caused by the investigational product. If no valid reason exists for suggesting a relationship, 
then the AE should be classified as “unrelated.” If there is any valid reason, even if 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 34 of 58 
CONFIDENTIAL  undetermined, for suspecting a possible cause- and-effect relationship between the investigational 
product and the occurrence of the AE, then the AE should be considered “related.” 
12.2.3. Recording Adv erse Event  
Adverse events spontaneously reported by the subject and/or in response to an open question 
from the study
 personnel or revealed by observation will be recorded during the study at the 
investigational site. Clinically significant changes in laboratory values, blood  pressure, and pulse 
need not be reported as AEs. However, abnormal values that constitute an SAE or lead to discontinuation of administration of study drug must be reported and recorded as an AE.  
Information about AEs will be collected from the signing o f the consent form until the end of the 
study. Serious adverse event information will be collected from signing of the consent form until 
the end of study participation. The AE term should be reported in standard medical terminology 
when possible. For each AE, the Investigator will evaluate and report the onset (date and time), resolution (date and time), intensity, causality, action taken, seriousness outcome (if applicable), and whether or not it caused the subject to discontinue the study. 
12.2.4. Intensity  
The intens i
ty of each AE will be graded using National Cancer Institute (NCI) Common 
Terminology C r
iteria f or Adverse Events (CTCAE)  v 4.03. The  criteria  can be accessed at: 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf . 
The term “severe” i s a meas ure of intensity. A sever e AE is not ne cessarily an SAE.  
Grade refers to the intensity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical des
criptions of intensity for each AE based on this general guideline: 
Grade 1  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only
; intervention not indicated 
Grade 2  Moderate; minimal, local, or noninvasive intervention 
indicated; limiting age -appropriate instrumental activities of 
daily living (ADL)  
Grade 3  Severe or medically significant but not immediately life -
threatening
; hospitalization or prolongation of the 
hospitalization indicated; disabling; limiting self -care ADL  
Grade 4  Life-threatening consequences; urgent intervention indicated 
Grade 5  Death related to AE  
It is important to distinguish between serious and severe AEs. Severity is a measure of intensity 
whereas ser
iousness is defined by the criteria under Section 12.2.1.2. An AE of severe intensity 
may or may not be considered serious. 
Should a pregnancy occur, it must be reported and recorded on the provided pregnancy form.  
Pregnancy i
n itself is not regarded as an AE unless there is a suspicion that an investigational 
product may have interfered with the effectiveness of a contraceptive medication. 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 35 of 58 
CONFIDENTIAL  The outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth, or 
congenital abnormality) must be followed up and documented even if the subject was discontinued from the study. 
All reports of congenital abnormalities/birth defects ar e SAEs. Sponta
 neous miscarriages should 
also be reported and handled as SAEs. Elective abortions without complications should not be 
handled as AEs. 
12.2.5. Reporting A dverse Events  
All SAEs (related and unrelated) will be recorded from the signing of the consent form until the end of study pa
rticipation. Any SAEs considered related to the investigational product and 
discovered by the Investigator at any time after the study should be reported. All SAEs must be 
reported to Clearside Biomedical, or its designee, within one business day of the first awareness 
of the event. The Investigator must complete, sign, and date the SAE pages, verify the accuracy of the information recorded on the SAE pages with the corresponding source documents, and send a copy by fax to Clearside Biomedical, or its designee.   
Additional follow-up information, if required or available, should be faxed to Clearside 
Biomedical
, or its designee, within one business day of receipt. The information should be 
recorded on a follow-up SAE form and placed with the original SAE information and kept with the appropriate section of the CRF and/or study file. 
Clearside Biomedical is responsible for notifying the relevant regulatory authorities of certain 
events. It i
s the Principal Investigator’s responsibility to notify the Institutional Review Board 
(IRB)/Independent Ethics Committee ( IEC) of all SAEs that occur at his or her site. Investigators 
will also be notified of all unexpected, serious, drug- related events (7/15 -Day Safety Reports) 
that occur duri ng the clinical study. Each site is responsible for notifying its IRB/IEC of these 
additional SAEs. 
12.2.6. Follow- up of AE s and SAEs  
All AEs and SAEs reported during study conduct must be followed until resolution, until the condition stabi
lizes, until the event is otherwise explained, or the subject is lost to follow-up.  
Subjects will be followed for any treatment- related SAEs reported at the end of participation 
until the condition stabilizes, the event is otherwise explained, the subject is lost to follow-up, or 
the subject withdraws consent.   
NOTE:  “Resolution” means the subject has returned to baseline state of health, or the 
Investiga
tor does not expect any further improvement in the subject’s condition or does not 
expect worsening of the AE.  
For a non-serious AE that is first identified on the last scheduled contact, the event must be recorded on the
 AE CRF with the current status noted, but no further follow-up needs to be 
performed.  
Post-Study SAEs:   Investig ators are not obligated to actively seek SAE information in former 
study participants; however, any new SAE reported by the subject to the Investigator that occurs 
after the last scheduled contact and is determined by the Investigator to be associated with the 
use of study drug, should be reported to the Sponsor. The Investigator should follow related 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 36 of 58 
CONFIDENTIAL  SAEs identified after the last scheduled contact until the event has resolved or stabilized or the 
subject is lost to follow -up.  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 37 of 58 
CONFIDENTIAL  13. STATISTIC AL CONSIDERATIONS  
A detailed statistical analysis plan will be prepared for this study.  Even though the endpoints in 
this study will only be based on descriptive statistics, the plan will contain a discussion of the statistical methods, a description of any computational algorithms and data handling 
conventions, and specifications for the data summaries and listings.  It will be finalized before 
database lock. No inferential statistical analyses will be performed. All safety and efficacy endpoints will be summarized using descriptive statistics.   
Pharmacokinetic analyses to determine systemic levels of triamcinolone acetonide following suprachoroidal
 injection will be described in a separate detailed plan.  
13.1. Determination of Sample Size  and Level of Significance  
Approximately 35 subjects will be enrolled in this open- label safety study.  Because this is a 
safety study, it was not powered for hypothesis testing; statistical analyses were descriptive in nature. The study sample size was not based on statistical calculations or statistical assumptions.  
13.2. Subject Disposi tion, Demographic and Baseline Characteristics  
Subject disposition, demographic, and baseline characteristics will be summarized descriptively . 
13.3. Analysis  Populations  
13.3.1. Safety  Population 
The safety population will include all subjects who are administered at least one dose of CLS- TA.  All analyse
s will be based on the Safety Population. 
13.3.2. Pharmacokinet ic Population  
The p harmacokinetic population will include all subjects who are administered at least one dose 
of CLS -TA. Analys es w
ill be conducted on all samples collected during the study.  
13.4. Analysis Methods 
Safety and efficacy endpoints are provided in S ection 7.12.  
13.4.1. Primary Safety  An alysis 
The primary endpoint is the incidence of treatment -emergent adverse even ts (TEAEs) and SAEs, 
grouped by organ system, relatedness to study medication, and severity. 
The TEAEs and SAEs will be summarized by system organ class (SOC) and preferred term (PT) 
by presenting t
he number and percentage of subjects with each TEAE and S AE. The  following 
AE summaries  will be produced:  
• TEAEs by SOC and PT  
• SAEs by SOC and PT  
• Treatment -related TEAEs b y SOC and PT  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 38 of 58 
CONFIDENTIAL  • Treatment -related SAEs by SOC and PT  
• TEAEs by SOC, PT, and maximum severity 
In the summary, subjects may be counted under multiple SOCs and PTs, but for each SOC and 
PT, subjects
 are only counted once. If a subject has the same AE on multiple occasions, the 
highest severity (severe, moderate, mild) recorded for the event will be presented and the highest 
drug relationship will be presented on the respective tables. Percentages are based on the number of subjects in the Safety population. 
All AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA).  
13.4.2. Secondary S afe
 ty Analysis 
Unless otherwise specified, all continuous variables will be summarized with descriptive 
statisti
cs including: the number of observation (n), mean, standard deviation, median, minimum 
and maximum.  All categorical/qualitative data will be pr esented using the number of 
observations (n), the frequency count and percentages by visit. The listings will be provided using the safety population. In general, the subject listings will be sorted by the subject number 
and assessment date (and time, if applicable).  
13.4.2.1. Extent of Exp
 osure 
The extent of exposure (the number of injections and whether it was a complete or partial injection) will b
e listed.  
13.4.2.2. Secondary S afety Endpoints 
• Percentage of subjects whose IOP increases are >5 and > 10 mmHg from their own 
baseline measu
rement at each follow -up visit (except Visits 2 & 5 [post-dose])  
• Percentage of subjects whose IOP increases to a reading > 30 mmHg at each follow -
up visit (ex
cept Visits 2 & 5 [post-dose]) 
• Percentage of subjects who require 1 or more additiona l IOP lowe ring medications at 
any follow -up visit (except Visits 2 & 5 [post-dose]) 
• Percentage of subjects who experience an 11 – 20 mm,  21-30 mm, >30 mm r ise in 
IOP 30 min post injection 
• Mean change in lens grading based on standardized cataract grading s ystem 
assessme
nt  
13.4.2.3. Additional E ndpoints  
• User evaluation and information pertaining to the use of the microinjector during the 
injection pr
ocedure  
• Triamcinolone acetonide blood concentrations prior to the each dose (Visits 2 and 5), 
4 weeks foll
owing the first dose (Visit 3) and at 24 weeks (Visit 8)  
• Percentage change in anterior chamber cells  and flare  and vitreous haze 
• Mean change from baseline in ETDRS BCVA   
• Mean chang
e from baseline in CST   
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 39 of 58 
CONFIDENTIAL  • Percentage of subjects with <300 micron CST 
• Percentage of subjects with a decrease in systemic concomitant uveitis medications  
• Percent
age of subjects in whom any additional therapy was initiated to manage 
uveitis  
13.4.2.4. S
ubgroup anal ysis 
No subgroup analyses are p lanned.  
13.4.3. Pharmacoki netic Analysis 
Standard  population PK parameters will be calculated from plasma CLS -TA conce ntrations. 
Samples from approximately 35 subjects enrolled in the study will be available for analysis. 
Analys es will be conducted according to the nonlinear mixed- effects approach and wi ll provide 
estimates of population characteristics (intrinsic and extrinsic factors) that d escribe the 
population distribution of the PK parameters. 
13.4.4. Procedure for Acco unting for Missing, Unused or Spurious Data   
Any missing, unused, or spurious data will be noted in the final clinical study report.  
No imputation is planned for safety data. Methodology for handling missing or partial dates will 
be addressed i
n the Statistical Analysis Plan.  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 40 of 58 
CONFIDENTIAL  14. DIRECT ACCESS TO SOURCE DOCUMENTS 
14.1. Study Monitoring  
Before an investigator  can enter a subject into the study, a representative of Clearside 
Biomedical, Inc will visit the study site  (unless waiver criteria are met)  to: 
• Determine the adequacy of the facilities  
• Discuss
 with the Investiga tor(s) and other personnel thei r responsibilities with regard to 
protocol adherence and the responsibilities of Clearside Biomedical, Inc or its 
representatives. This will be documented in a Clinical Study Agreement between Clearside Biomedical , Inc and the Investigator. 
During the study, a monitor from Clearside Biomedical, Inc or its representative will have regular c
ontacts with the study site to : 
• Provide information and support to the Investigator (s) 
• Confir
m that facilities remain acceptable  
• Confirm th
at the investigational team is a dhering to t he protocol, that data are being 
accurately recorded in the CRF s, and that investigational product accountability checks 
are being performed  
• Perform source data verification. This includes a comparison of the data in the CRF s with 
the s
ubject ’s medical records at the hospital or practice, and other records relevant to the 
study. This will require direct access to all original records for each subject (eg , clinic 
charts).  
• Record and report any protocol deviations not previously sent to Clearside Biomedical,  
Inc or designee.  
• Confirm AEs and SAEs have been properly documented on CRFs and confirm any SAEs have been forw
arded to Clearside Biomedical, Inc or designee and those SAEs that met 
criteria for reporting have been forwarded to the IRB/IEC.  
The monitor will be available between visits if the Investigator (s) or other st aff needs 
information or advice. 
14.2. Audits and Inspections  
Authorized representatives of Clearside Biomedical, a regulatory authority, an Independent Ethics Committee or an Institutional Review Board may visit the study site to perform audits or inspections, including source data verification. The purpose of a Clearside Biomedical audit or 
inspection is to systematically and independently examine all study -related activities and 
documents to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurately reported according to the protocol, Good Clinical Practice guidelines of the International Conference on Harmonization, and any applicable regulatory requirements.  
The Investigator should contact Clearside Biomedical immediately if contacted by a regulatory agency about an inspection. 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 41 of 58 
CONFIDENTIAL  14.3. Institutional Review Boards/Independent Ethics Committees  
The Principal Investigator must obtain IRB/IEC approval for the investigation. Initial IRB/IEC 
approval and all materials approved by the IRB/IEC for this study, including the subject consent form and recruitment materials, must be maintained by the Investigator and made available for inspection. 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 42 of 58 
CONFIDENTIAL  15. QUALITY CONTROL  AND QUALITY ASSURANCE  
The progress of the study will be monitored by onsite, written, e-mail, and telephone 
communications between personnel at the study site and the Sponsor. The Investigator will allow Sponsor monitors, or designee(s), to inspect all CR Fs; subject records (source documents); 
signed Informed Consent Forms; records of study drug receipt, storage, and disposition; and regulatory files related to the study.  
At the time of database lock, the clinical database will be audited to ensure accuracy of the data, 
as well as
 to provide an estimated error rate for the final, locked database. The audit will involve 
a comparison of CRF values with values from data listings generated from the clinical database. 
Values identified as critical safety and eff icacy variables will be confirmed for 100% of the 
subjects. In addition, a random sample of subjects will be selected for which all data values, excluding comment fields, will be checked. The number of subjects whose data will be randomly reviewed will be determined to provide sufficient accuracy for the estimated error rate of the clinical database.  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 43 of 58 
CONFIDENTIAL  16. ETHICS 
16.1. Ethical Review 
The final study protocol, including the final version of the Informed Consent Form, must be 
approved or given a favorable opinion in writing by an IRB or IEC as appropriate. The 
Investigator must submit written approval to Clearside Biomedical, Inc, or designee, before he or she can enroll any subject into the study. 
The Principal Investigator is responsible for informing the IRB or IEC of any amendment to the 
protocol in acc
ordance with local requirements. In addition, the IRB or IEC must approve all 
advertising used to recruit subjects for the study. The protocol must be re-approved by the IRB or IEC upon receipt of amendments and annuall y, as local regulations require.  
The Principal Investigator is also responsible for providing the IRB or IEC with reports of any reportable  s
erious adverse drug reactions from any other study conducted with the investigational 
product. Clearside Biomedical, Inc will provide this information to the Principal Investigator. 
Progress reports and notifications of serious adverse drug reactions will be provided to the IRB 
or IEC acc
ording to local regulations and guidelines. 
16.2. Ethical Conduct of the Study  
The stud y will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with the International Council for Harmonisation Guideline for Good Clinical Practice, and applicable regulatory requirements. 
16.3. Written Informed C onsent  
The Principal Investigator(s) at each site will ensure that the subject is given full and adequate 
oral and written information about the nature, purpose, and possible risk and benefit of the study.  
Subjects must also be notified that they are free to discontinue from the study at any time. The subject should be given the opportunity to ask questions and allowed time to consider the information provided. 
The subject’s signed and dated informed consent must be obtained before conducting any study 
procedures. 
T
he Principal Investigator(s) must maintain the original, signed Informed Consent Form. A copy 
of the signe
d Informed Consent Form must be given to the subject.   
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 44 of 58 
CONFIDENTIAL  17. DATA HANDLING AND RE CORDKEEPING  
17.1. Inspection of Records  
Clearside Biomedical  Inc, and designees, will be allowed to conduct site visits to the 
investigation facilities for the purpose of monitoring any aspect of the study. The Investigator 
agrees to allow the monitor to inspect the drug storage area, study drug stocks, drug accountability records, subject charts and study source documents, and other records relative to study conduct. 
17.2. Retention of Records 
The Principal Investigator must maintain all documentation relating to the study for a period of 2 years after the last marketing application approval, or if not approved, 2 years after the 
discontinuance of the test article for investigation or according to local regulation. If it becomes 
necessary for Clearside Biomedical, Inc or the Regulatory Authority to review an y 
documentation relating to the study, the Investigator must permit access to such records. 
  
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 45 of 58 
CONFIDENTIAL  18. PUBLICATION POLICY 
The institutions and Investigators participating in this study shall have no right to publish or 
present the results of this study without the prior written consent of Clearside Biomedical, Inc. 
CLS-TA, triamcinolone acetonide injectable suspension                                                       Clearside Biomedical, Inc   
CLS1001-302  Clinical Protocol  
 
27 April 2017  Page 46 of 58 
CONFIDENTIAL  19. REFERENCES  
Bodaghi B, Cassoux N, Bertrand W, et al. Chronic severe uveitis: etiology and visual outcome in 
927 patients from a single center. Medicine. 2001;80:263-270. 
Dick AD. The treatment of chronic uveitic macular edema. Br J Ophthalmol. 1994;78:1-2. 
Goldste in DA, Pyatetsky D, Tessler HH.  Classific ation, s ymptoms, and signs of uveitis. Duane’s 
Ophthalmology on DVD-ROM Ed 2009a:chap 32. Goldstein DA, Do D, Noronha G et al. Suprachoroidal corticosteroid administration: a novel 
route for loca
l treatment of noninfectious uveitis. Trans Vis Sci Tech. 2016;5(6):14, 
doi:10.1167/tvst.5.6.14. 
Karim R, Sykakis E, Lightman S, Fraser-Bell S. Interventions for the treatment of uveitic 
macular edema: a s
ystematic review and meta-analysis. Clin Opthalmol. 2013;7:1109-1144. 
Lardenoye C, Kooji B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology
. 2006;113:1446-1449. 
Lowder C, Belfort R, Lightman S, et al. Dexamethasone Intravitreal Implant fo r Noninfecti ous 
Intermediate or Posterior Uveitis. Arch Ophthalmol. 2011;129(5):545-553. 
Miserocchi E, Fogliato G, Modorati G and Bandello F. Review on the worldwide epidemiology 
of uveitis. Eur
 J Ophthalmol. 2013;23:705-717. 
Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity i
n intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467- 471. 
Rothova A, Suttorp-van Schulten SA, Treffers WF and Kijlstra A. Causes and frequency of 
blindness in pat
ients with intraocular inflammatory disease. Br J Ophalmol. 1996;80:332-336. 
SUN Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results from the fir
st international workshop. Am J Ophthalmol 2005;150:509-516. 
Triesence [ Prescri bing I nformation]. Fort Worth, Texas: Alcon Laboratories, Inc., 2007. 
Wood B. An overview of uveitis and its management. US Pharmacist 2011. 
CLS1001- 302 Clinical Protocol  Clearside Biomedical, Inc.  
27 April 2017  Page 47 of 58 
CONFIDENTIAL  20. APPENDICES  
 
CLS1001- 302 Clinical Protocol  Clearside Biomedical, Inc.  
27 April 2017  Page 48 of 58 
CONFIDENTIAL  APPENDIX A.  TIME  AND EVENTS SCHEDULE  
Visit #  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  Visit 8 
Visit Type  Screening  Treatment #1 Follow -Up Treatment #2  Follow -Up End of 
Study  
Visit Window  Day -30 to 0 Day 0 Week 4  
Day 28 ± 5  Week 8  
Day 56 ± 5  Week 12  
Day 84 ± 5  Week 16  
Day 1 12 ± 5  Week  20 
Day 140 ± 5  Week 24  
Day 168 ± 5  
Assessments   Pre-dose5 Post-
dose   Pre-dose  Post-dose    
Informed Consent  √          
Assign Subject 
Number  √          
Demographics, 
Medical & Ocular 
History  √          
Eligibility Criteria  √ √         
Assess AEs  √ √ √ √ √ √ √ √ √ √ 
Con Med Review  √ √ √ √ √ √ √ √ √ √ 
Resting HR & BP  √ √    √    √ 
Lab Tests1 √         √ 
Review of Body 
Systems  √         √ 
BCVA4 √ √  √ √ √  √ √ √ 
Slit lamp 
Biomicroscopy2, 4 √ √ √ √ √ √ √ √ √ √ 
IOP6 √ √ √ √ √ √ √ √ √ √ 
CLS1001- 302 Clinical Protocol  Clearside Biomedical, Inc.  
27 April 2017  Page 49 of 58 
CONFIDENTIAL  Visit #  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  Visit 8 
Visit Type  Screening  Treatment #1 Follow -Up Treatment #2  Follow -Up End of 
Study  
Visit Window  Day -30 to 0 Day 0 Week 4  
Day 28 ± 5  Week 8  
Day 56 ± 5  Week 12  
Day 84 ± 5  Week 16  
Day 1 12 ± 5  Week  20 
Day 140 ± 5  Week 24  
Day 168 ± 5  
Assessments   Pre-dose5 Post-
dose   Pre-dose  Post-dose    
Dilated Indirect 
Ophthalmoscopy4 √ √ √ √ √ √ √ √ √ √ 
SD-OCT4 √ √  √ √ √  √ √ √ 
PK Blood Draw   √  √  √    √ 
Select Study 
Eye/Confirm Study 
Eye √     √     
Fluorescein 
Angiogram4 √         √ 
Fundus Photos4 √         √ 
Study Drug 
Treatment3   
       
1. Central lab test samples should be collected prior to fluorescein angiogram being performed; local labs include a urine or serum pregnancy 
test for females of child bearing potential  
2. Any finding of cataract should be graded  
3. Injection should be administere d the same d ay as the pre- injection assessments at Visit 1/2 and at Visit 5 
4. Completed for both eyes at Visit 1 and Visit 8 ; study ey e only for all other visits  
5. If Visit 1 and Visit 2 occur on the same day, the Screening procedures can replace the Pre- dose procedur es of Visit 2  
6. IOP collected for both eyes, except post -injectio n when data are collected for study eye only  
  INJECT3 INJECT3 
CLS1001- 302 Clinical Protocol  Clearside Biomedical, Inc.  
27 April 2017  Page 50 of 58 
CONFIDENTIAL  APPENDIX B:   SUMMARY OF CHANGES  
CLS1001- 302 Clinical Protocol  Clearside Biomedical, Inc.  
27 April 2017  Page 51 of 58 
CONFIDENTIAL  Amendment  1 
Section Changed  
 
 Initial Protocol 1.0  
(Changed From)  Protocol version 2.0  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Throughout protocol  
 
 Miscellaneous typographical 
and formatting errors as well as 
clarifications for readability   To correct typographical and formatting errors  and improve 
readability   None  
Cover page  1220 Old Alpharetta Rd., Suite 300 
Alpharetta, GA  30005  900 North Point Parkway, Suite 200 
Alpharetta, GA  30005  Clearside Biomedical, Inc. Address cha
nge None  
List of Abbreviations   PK – Pharmacokinetics To include  the term:  
pharmacokin
etics (PK)  None  
7.2.3. Additional Endpoints 
and 13.4.2.3. Additional 
Endpoints  Percentage change in anterior chamber cells
 and vitreous haze Percentage change in anterior 
chamber cells
 and flare, and 
vitreous haze  To include percentage change in flare as  a 
n additional 
endpoint  None  
Section 8.2.1. Ophthalmic 
Exclusion Criteria #5   History of any vitreoretinal surgery (exa
mples include but 
are not limited to scleral buckle, 
retrieval of a dropped nucleus or intraocular lens) in the study 
eye; prior photocoagulation and 
IVT injections are acceptable; prior cataract extraction, 
Yttrium -Aluminum -Garnet 
laser capsulotomy, and pars 
plana vitrectomy is allowed, but 
must ha ve been performed at 
least 3 months prior to Visit 2  To exclude subjects who have 
had vitreor
etinal surgery except 
the allowed surgeries that are listed.  None  
CLS1001- 302 Clinical Protocol  Clearside Biomedical, Inc.  
27 April 2017  Page 52 of 58 
CONFIDENTIAL  Amendment  1 
Section Changed  
 
 Initial Protocol 1.0  
(Changed From)  Protocol version 2.0  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Section 8.2.1. Ophthalmic 
Exclusion Criteria # 6 Has had cyclodestructive procedures or
 filtration 
surgeries in the study eye in the 3 months prior to Visit 2  Has had cyclodestructive procedur
es, filtration surgeries, 
or laser trabeculoplasty in the study eye in the 3 months prior to Visit 2  To exclude subjects who have had laser trab
eculoplasty  None  
CLS1001- 302 Clinical Protocol  Clearside Biomedical, Inc.  
27 April 2017  Page 53 of 58 
CONFIDENTIAL  Amendment  1 
Section Changed  
 
 Initial Protocol 1.0  
(Changed From)  Protocol version 2.0  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Section 8.2.2. General 
Exclusion Criteria #17, 18, & 19  17. Has taken systemic 
corticost
eroids at doses greater 
than 20 mg per day for oral prednisone (or equivalent for other corticosteroids) in the 2 
weeks prior to Visit 2; subjects 
on 20 mg or less per day can be enrolled; decreases and 
termination of dose are 
allowable during the study  
18. Is currently using 
prescribed
 nonsteroidal anti -
inflammatory drugs (excluding over the counter use) unless the 
dose has been stable for at least 
2 weeks p rior to Visit 2, 
decreases and termination of 
dose are allowable during the 
study  
19. Is currently using 
prescribe
d immunomodulatory 
therapies, unless the dose has been stable for at least 2 weeks 
prior to Visit 2; decreases and 
termination of dose are allowable during the study To clarify that decreases or termination
 in doses of systemic 
corticosteroid, immunomodulatory and NSAID therapy are allowed during the study  None  
CLS1001- 302 Clinical Protocol  Clearside Biomedical, Inc.  
27 April 2017  Page 54 of 58 
CONFIDENTIAL  Amendment  1 
Section Changed  
 
 Initial Protocol 1.0  
(Changed From)  Protocol version 2.0  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Section 8.4. Visit Procedure 
Descriptions & Appendix A  All ocular assessments at Visit 1 and Visit 8 
will be performed 
on both eyes. Data for ocular assessments at all other visits (Visits 2 -7) will be collected on 
the study eye only.  
5. Perform ophthalmic 
assessm
ents on the study eye 
only:  
a. ETDRS BCVA  
b. Slit-lamp biomicroscopy  
a. IOP (Gol
dmann 
applanatio
n tonometry)  
c. Dilated ophthalmoscopy  
d. SD-OCT and upload 
images to
 the CRC  
 All ocular assessments at Visit 1 and Visit  8 
will be performed 
on both eyes.  IOP will be collected in both eyes at all visits. All other ocular 
assess ments at all other visits 
(Visits 2 -7) will be collected on 
the study eye only.  
5. Perform ophthalmic 
assessm
ents on the study eye 
only, unless otherwise designated:  
a. ETDRS BCVA  
b. Slit-lamp biomicroscopy  
a. IOP (Gol
dmann 
applanatio
n tonometry, both 
eyes) 
c. Dilated ophthalmoscopy  
d. SD-OCT and upload 
images to
 the CRC  To collect IOP data on the 
fellow eye a
t all visits for 
comparison to the study eye IOP Additional risk common to IOP collection p
rocedure  
Section 8.4. Visit Procedure Descriptions  Slit-lamp biomicroscopy  Slit-lamp biom
 icroscopy, 
including
 dilated lens grading  To be consistent with the Time 
and Event
s Schedule (Appendix 
A) None  
CLS1001- 302 Clinical Protocol  Clearside Biomedical, Inc.  
27 April 2017  Page 55 of 58 
CONFIDENTIAL  Amendment  1 
Section Changed  
 
 Initial Protocol 1.0  
(Changed From)  Protocol version 2.0  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
9.4.1. Rescue Criteria  A ≥ 1.5 -step increase from 
baseline (
Day 0) in the level of 
inflammation (eg,  anterior 
chamber cells  or vitreous haze) 
or an increase from 3+ to 4+ A ≥ 1.5 -step increase from 
baseline (
Day 0) in the level of 
inflammation (eg, anterior 
chamber cells or flare, or vitreous haze) or an increase from 3+ to 4+  To include anterior chamber  
flare as an ex
ample of a sign of 
inflammation  None  
  A decrease of 10 or more ETDRS BCV
A letters read 
from the best ETDRS BCVA data observed during the study, along with an increase in other 
signs or complications 
associated with the patient’s  
uveitis  To ensure that any subjects who experience a s ubs
tantial 
decrease in BCVA, along with worsening of uveitis, receive appropriate treatment  This additional criterion  will 
ensure that
 study eyes are never 
undertreated  
13. Statistical Considerations   Pharmacokinetic analyses to determine sy
stemic levels of 
triamcinolone acetonide 
following suprachoroidal 
injection will be described in a separate detailed plan.  To include  an analysis o
 f the 
pharmacokinetic data collected  None  
CLS1001- 302 Clinical Protocol  Clearside Biomedical, Inc.  
27 April 2017  Page 56 of 58 
CONFIDENTIAL  Amendment  1 
Section Changed  
 
 Initial Protocol 1.0  
(Changed From)  Protocol version 2.0  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Section 2. Synopsis and 
Section 6.2. Secondary 
Objectives  
 
 
 
  The secondary objectives of the study are:  
• T
o assess changes to signs 
and comp
lications of uveitis  
• To collect use information 
on the supra
choroidal injection 
procedure  
 The secondary objectives of the study are: 
• To
 assess changes to signs 
and comp
lications of uveitis  
• To collect use information 
on the supra
choroidal injection 
procedure  
• To determine systemic 
exposure t
o triamcinolone 
acetonide after suprachoroidal 
injection  To include  an objective f or 
determining the systemic 
exposure to triamcinolone acetonide after suprachoroidal injection  None  
Section 7.1 Overall Study Design , Section 7.2.3. 
Additional Endpoints,  and 
Section 13.4.2.3. Additional Endpoints   • Triamcinolone acetonide 
blood concent
rations  prior to 
the first dose (Visit 2), 4 weeks 
follo wing the first dose (Visit 
3), 12 weeks following the first 
dose (and prior to the second dose, Visit 5) and at 12 weeks 
after the second dose (24 weeks, Visit 8)  To describe the timing of blood 
draws fo
r collection of  
pharmacokinetic data from all subjects  None  
Section 8.4. Visit Procedure 
Descriptions  and Appendix A   Collect a blood sample for PK analysis; f 
or Visit 2 and 5; 
blood must be collected PRIOR 
to dosing To collect blood samples for 
pharmacokin
etic data from all 
subjects  There is an additional risk common to blood 
draw 
procedures  
CLS1001- 302 Clinical Protocol  Clearside Biomedical, Inc.  
27 April 2017  Page 57 of 58 
CONFIDENTIAL  Amendment  1 
Section Changed  
 
 Initial Protocol 1.0  
(Changed From)  Protocol version 2.0  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
11.3. Pharmacokinetics 
Assessments   Blood samples for measurement of CLS -TA plas 
ma 
concentrations will be collected by venipuncture by qualified study perso nnel. A single blood 
sample will be obtained from each subject at the following time points: Day 0 (Visit 2) pre -
dose, Week 4 (Visit 3) any time during visit, Week 12 (Visit 5) pre-dose and Week 24 (Visit 8) 
any time during visit. Blood samples will be pro cessed and 
shipped to a central lab as 
outlined in the manual of 
procedures for the study.  To describe the collection of 
blood sample s
 for 
pharmacokinetic analysis  None  
13.3.2. Pharmacokinetics 
Population   Pharmacokinetic population will include
 all subje cts who are 
administered at least one dose 
of CLS -TA. Analysis will be 
conducted on all samples collected during the study.  To describe the population to be 
included i
n pharmacokinetic 
analysis  None  
CLS1001- 302 Clinical Protocol  Clearside Biomedical, Inc.  
27 April 2017  Page 58 of 58 
CONFIDENTIAL  Amendment  1 
Section Changed  
 
 Initial Protocol 1.0  
(Changed From)  Protocol version 2.0  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Section 13.4.3. 
Pharmacokinetics Analysis   Standard population PK  
parameters will be calculated 
from plasma CLS -TA 
concentrations. Samples from 
approximately 35 subjects 
enrolled in the study will be 
available for analysis. Analyses will be conducted according to 
the nonlinear mixed -effects 
approach and wil l provide 
estimates of population characteristics (intrinsic and 
extrinsic factors) that describe the population distribution of the PK parameters. To describe the analysis of 
pharmacoki
netic data  None  
Section 12.1.9. Resting Heart Rate and Blood Pressu re Resting heart rate and resting blood pressur
e (systolic and 
diastolic, preferably on the same group each time) will be measured at every visit after the 
subject has rested for about 5 
minutes.  Resting heart rate and resting blood pressur
e (systolic and 
diastolic, preferably on the same group each time) will be measured at Visits 1, 2, 5 and 8 
after the subject has rested for 
about 5 minutes.  To clarify that resting heart rate and resting
 blood pressure 
should be measured at specified visits  None  
 